HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NE 58051

inhibits tumor cell adhesion to extracellular matrices; structure in first source

Also Known As:

3-(3-pyridyl)-1-hydroxypropylidene bisphosphonic acid; NE-58051

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphonates: 424
    - Diphosphonates: 11565
      - NE 58051: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - NE 58051: 3

Experts

1.	Clézardin, Philippe: 1 article (07/2010)
2.	Ebetino, Frank H: 1 article (07/2010)
3.	Fournier, Pierrick G: 1 article (07/2010)
4.	Stresing, Verena: 1 article (07/2010)
5.	Boissier, S: 1 article (06/2000)
6.	Clézardin, P: 1 article (06/2000)
7.	Colombel, M: 1 article (06/2000)
8.	Delaissé, J M: 1 article (06/2000)
9.	Delmas, P: 1 article (06/2000)
10.	Ebetino, F H: 1 article (06/2000)

Related Diseases

1.	Neoplasms (Cancer) 09/15/1997 - "NE-58051, the inactive pyridylpropylidene analogue of risedronate, had no inhibitory effect on tumor cell adhesion compared to that observed with its active counterpart NE-10244, suggesting that the mechanism of action of BP on tumor cells involved a stereospecific recognition step. " 07/01/2010 - "In contrast to NE-58051, risedronate did inhibit B02 breast cancer bone metastasis formation by reducing both bone destruction and skeletal tumor burden, indicating that the antitumor effect of bisphosphonates is achieved mainly through inhibition of osteoclast-mediated bone resorption." 06/01/2000 - "In addition, NE-58051 (the inactive pyridylpropylidene analogue of risedronate) had no inhibitory effect, whereas NE-10790 (a phosphonocarboxylate analogue of risedronate in which one of the phosphonate groups is substituted by a carboxyl group) inhibited tumor cell invasion to an extent similar to that observed with NE-10244, indicating that the inhibitory activity of BPs on tumor cells involved the R2 chain of the molecule. "
2.	Neoplasm Metastasis (Metastasis) 07/01/2010 - "In vivo, risedronate and NE-58051 did not inhibit the growth of subcutaneous B02 breast tumor xenografts or the formation of B16F10 melanoma lung metastasis. " 07/01/2010 - "In contrast to NE-58051, risedronate did inhibit B02 breast cancer bone metastasis formation by reducing both bone destruction and skeletal tumor burden, indicating that the antitumor effect of bisphosphonates is achieved mainly through inhibition of osteoclast-mediated bone resorption."
3.	Melanoma (Melanoma, Malignant) 07/01/2010 - "In vitro, risedronate and NE-58051 inhibited proliferation of breast cancer and melanoma cell lines. " 07/01/2010 - "In vivo, risedronate and NE-58051 did not inhibit the growth of subcutaneous B02 breast tumor xenografts or the formation of B16F10 melanoma lung metastasis. "
4.	Breast Neoplasms (Breast Cancer) 07/01/2010 - "In vitro, risedronate and NE-58051 inhibited proliferation of breast cancer and melanoma cell lines. " 07/01/2010 - "In vivo, risedronate and NE-58051 did not inhibit the growth of subcutaneous B02 breast tumor xenografts or the formation of B16F10 melanoma lung metastasis. " 07/01/2010 - "In contrast to NE-58051, risedronate did inhibit B02 breast cancer bone metastasis formation by reducing both bone destruction and skeletal tumor burden, indicating that the antitumor effect of bisphosphonates is achieved mainly through inhibition of osteoclast-mediated bone resorption."
5.	Bone Resorption 07/01/2010 - "In contrast to NE-58051, risedronate did inhibit B02 breast cancer bone metastasis formation by reducing both bone destruction and skeletal tumor burden, indicating that the antitumor effect of bisphosphonates is achieved mainly through inhibition of osteoclast-mediated bone resorption."

Related Drugs and Biologics

1.	Risedronic Acid (Actonel)
2.	NE 10244
3.	Organophosphonates (Phosphonates)
4.	Diphosphonates (Bisphosphonates)
5.	2- (3- pyridinyl)- 1- hydroxyethylidene- 1,1- phosphonocarboxylic acid